VANI

Vivani Medical Inc

Add to Watchlist

Advanced Chart

1.030

0.000(0.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

1.040

Open

1.020

VWAP

1.02

Vol

39.84K

Mkt Cap

61.02M

Low

1.010

Amount

40.73K

EV/EBITDA(TTM)

Total Shares

54.98M

48.01M

EV/OCF(TTM)

P/S(TTM)

Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Company’s lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Company’s implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.

2 Analyst Rating

288.35% Upside

Wall Street analysts forecast VANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VANI is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

288.35% Upside

Current: 1.030

Low

4.00

Averages

4.00

High

4.00

288.35% Upside

Current: 1.030

Low

4.00

Averages

4.00

High

4.00

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-04-16

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-04-16

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-04-04

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-04-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-03-26

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-03-26

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-03-13

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-03-13

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Initiates

2024-11-07

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2024-11-07

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Vivani Medical Inc (VANI.O) is -2.52, compared to its 5-year average forward P/E of -2.29. For a more detailed relative valuation and DCF analysis to assess Vivani Medical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.29

Current PE

-2.52

Overvalued PE

-1.18

Undervalued PE

-3.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.14

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.13

Undervalued EV/EBITDA

-3.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q1

N/A

Total Revenue

FY2025Q1

YoY :

+5.30%

-6.56M

Operating Profit

FY2025Q1

YoY :

-100.00%

N/A

Net Income after Tax

FY2025Q1

YoY :

-8.33%

-0.11

EPS - Diluted

FY2025Q1

YoY :

+10.10%

-5.17M

Free Cash Flow

FY2025Q1

N/A

Gross Profit Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

271.4K

USD

Months

3-6

1.1K

USD

Months

6-9

5.0M

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

271.4K

USD

Months

3-6

1.1K

USD

Months

6-9

5.0M

USD

Months

0-12

0.0

USD

Months

VANI News & Events

Events Timeline

2025-04-15 (ET)

2025-04-15

08:38:58

Vivani Medical, Okava expand collaboration to develop OKV-119 for dogs

2025-03-31 (ET)

2025-03-31

07:35:45

Vivani Medical to focus on developing NPM-115, NPM-139, emerging pipeline

2025-03-31

07:35:09

Vivani Medical announces anticipated upcoming milestones

News

1.0

05-07Newsfilter

Vivani Medical to Present at the American Association of Pharmaceutical Scientists' "Beyond GLP1s: Where the Science will Take Business Next" Virtual Workshop

1.0

04-16Newsfilter

Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company

4.0

04-16Benzinga

HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target